Amgen announced that the FDA has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv (etelcalcetide)...
Amgen has announced that the European Commission (EC) has granted marketing authorization for Parsabiv (etelcalcetide) for the treatment of secondary...
Amgen has announced the Journal of the American Medical Association (JAMA) publication of findings from three Phase III studies of...
Amgen announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with...
Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.